Leadership

Target ALS Team

We have built a team that brings together a unique mix of clinical, scientific, business, and philanthropic expertise.

Manish Raisinghani

Manish Raisinghani, M.B.B.S., Ph.D.

Chief Executive Officer

Target ALS

Kenneth Devaney

Kenneth Devaney

Chief Operations Officer

Steve Schonberg

Steve Schonberg

Director of Communications

Burhan Siddiqui

Burhan Siddiqui

Accounting & Financial Systems Manager

Foundation Advisors

Our Foundation Advisors guide the Target ALS administration in ensuring that we are following best-in-class scientific approaches in our work, and they keep us closely connected to the latest developments in the field.

Chris Henderson

Chris Henderson, Ph.D.

Chief Advisor, Target ALS

VP, Head of Research, Biogen

Leonard Petrucelli

Leonard Petrucelli, Ph.D.

Chief Scientific Advisor, Target ALS

Professor of Neuroscience, Mayo Clinic

Board Members

The Target ALS Board of Directors sets overall policy and provides guidance to the Foundation’s executive leadership team. To ensure we craft truly groundbreaking strategies to foster collaboration and accelerate drug discovery and development, we have recruited a renowned, passionate group of pioneering academic leaders, pharmaceutical and biotech executives, patients and their family members, and visionary philanthropists.

John Dunlop

John Dunlop

Vice President, Neuroscience Research,

Amgen

Zach Hall

Zach Hall, Ph.D.

Chair, Target ALS COI Committee

Former Director, NIH NINDS

Richard Hargreaves

Richard Hargreaves, Ph.D.

Corporate Vice President,

Bristol-Myers Squibb

Carole Ho

Carole Ho, M.D.

Chief Medical Officer & Head of Development,

Denali Therapeutics

Story Landis

Story Landis, Ph.D.

Former Director, NIH NINDS

Mike Poole

Mike Poole, M.D.

Senior Advisor & Head,

COVID-19 Therapeutics Accelerator,
Bill and Melinda Gates Foundation

Stacie Weninger

Stacie Weninger, Ph.D.

President,

F-Prime Biomedical Research Initiative

Independent Review Committee

To avoid Conflicts of Interest (COI), all board and committee members, as well as staff, abide by a comprehensive COI policy and are neither allowed to apply for, nor receive funding from, Target ALS. The committee is chaired by Robert Miller, Ph.D., George Washington University.

Michael Ahlijanian

Michael Ahlijanian, Ph.D

Chief Scientific Officer,

Pinteon Therapeutics

Manzoor Bhat

Manzoor Bhat, Ph.D., M.S.

Professor & Chair, Dept. of Cellular & Integrative Physiology,

UT Health Science Center, San Antonio

Moses Chao

Moses Chao, Ph.D.

Professor, Department of Neuroscience
and Physiology,

New York University

Kenneth Fischbeck

Kenneth Fischbeck, M.D.

NIH Distinguished Investigator,

NIH NINDS

Jonathan Glass

Jonathan Glass, M.D.

Professor of Neurology & Pathology, Director of the Emory ALS Center,

Emory University

Zaven Kaprielian

Zaven Kaprielian, Ph.D.

Project Chief Scientific Officer,

Dementia Discovery Fund U.S.

Jim Kupiec

Jim Kupiec, M.D.

Chief Medical Officer,

ProMIS Neurosciences, Inc.

Lynne Maquat

Lynne Maquat, Ph.D.

Director, Center for RNA Biology,

University of Rochester Medical Center

Jere Meredith, Jr.

Jere Meredith, Jr., Ph.D.

Senior Director Neuroscience,

Arvinas

Robert Mays

Robert Mays, Ph.D.

Vice President of Regenerative Medicine & Head of Neuroscience Programs,

Athersys

Richard Olson

Richard Olson, Ph.D.

Director, Small Molecule Drug Discovery

Bristol Myers Squibb

Mahendra Rao

Mahendra Rao, M.D., Ph.D.

Chief Executive Officer,

panCELLa

Rajiv Ratan

Rajiv Ratan, M.D., Ph.D.

Executive Medical Director,
Burke Neurological Institute,

Cornell University

Ian Reynolds

Ian Reynolds, Ph.D.

Chief Executive Officer,

Rewind Therapeutics

Eric Schaeffer

Eric Schaeffer, Ph.D.

Chief Scientific Officer

Apres Therapeutics

Tracy Saxton

Tracy Saxton, Ph.D.

Managing Director

Dolby Family Ventures

Holly Soares

Holly Soares, Ph.D.

Head of Precision Medicine, VP,

Pfizer

Ajay Verma

Ajay Verma, M.D., Ph.D.

Executive Vice President, Head of Research and Development,

Yumanity Therapeutics

Frank Walsh

Frank Walsh, Ph.D.

Founder and Chief Executive Officer,

Ossianix

Andrew Wood

Andrew Wood, Ph.D.

VP, Clinical Neuroimaging Research,

CHDI

Conflict of Interest Committee

The Target ALS Conflict of Interest Committee ensures that the Independent Review Committee has no stake in projects selected and addresses any conflict of interest issues raised by the research community.

The committee is chaired by Zach Hall, Ph.D., Former Director of National Institute of Neurological Disorders and Stroke.

Daniel L. Doctoroff

Daniel L. Doctoroff

Founder & Board Chair, Target ALS

Founder & CEO, Sidewalk Labs

Lisa Ellerby

Lisa Ellerby, Ph.D.

Professor,

Buck Institute for Research on Aging

Robert Miller

Robert Miller, Ph.D.

Chair, Target ALS IRC

Interim Vice Dean for Research & Academic Affairs, George Washington University

Neil Shneider

Neil Shneider, M.D., Ph.D.

Director, Eleanor and Lou Gehrig ALS Center

Columbia University

James Treanor

James Treanor, Ph.D.

Board Member and Former CEO,

ADRx